AU2009246112B2 - Method of treating chronic heart failure - Google Patents

Method of treating chronic heart failure Download PDF

Info

Publication number
AU2009246112B2
AU2009246112B2 AU2009246112A AU2009246112A AU2009246112B2 AU 2009246112 B2 AU2009246112 B2 AU 2009246112B2 AU 2009246112 A AU2009246112 A AU 2009246112A AU 2009246112 A AU2009246112 A AU 2009246112A AU 2009246112 B2 AU2009246112 B2 AU 2009246112B2
Authority
AU
Australia
Prior art keywords
relaxin
heart failure
heart
subject
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009246112A
Other languages
English (en)
Other versions
AU2009246112A1 (en
Inventor
Thomas Dschietzig
Dennis R. Stewart
Sam L. Teichman
Elaine Unemori
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corthera Inc
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of AU2009246112A1 publication Critical patent/AU2009246112A1/en
Application granted granted Critical
Publication of AU2009246112B2 publication Critical patent/AU2009246112B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2009246112A 2008-05-16 2009-05-15 Method of treating chronic heart failure Ceased AU2009246112B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US61/127,889 2008-05-16
US19054508P 2008-08-28 2008-08-28
US61/190,545 2008-08-28
US20124008P 2008-12-08 2008-12-08
US61/201,240 2008-12-08
PCT/US2009/044247 WO2009140657A2 (en) 2008-05-16 2009-05-15 Method of treating chronic heart failure

Publications (2)

Publication Number Publication Date
AU2009246112A1 AU2009246112A1 (en) 2009-11-19
AU2009246112B2 true AU2009246112B2 (en) 2013-05-02

Family

ID=41319370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009246112A Ceased AU2009246112B2 (en) 2008-05-16 2009-05-15 Method of treating chronic heart failure

Country Status (10)

Country Link
US (3) US20110144019A1 (enExample)
EP (2) EP3150219A1 (enExample)
JP (3) JP2011520917A (enExample)
CN (2) CN104815319A (enExample)
AU (1) AU2009246112B2 (enExample)
BR (1) BRPI0912559A2 (enExample)
CA (1) CA2724535A1 (enExample)
MX (2) MX2010012502A (enExample)
RU (1) RU2512933C2 (enExample)
WO (1) WO2009140657A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
BR112012022654A2 (pt) 2010-03-10 2016-11-01 Univ Florida modulação de aquaporinas com relaxina
US20130336979A1 (en) * 2010-12-01 2013-12-19 Fatima Smih Diagnostic and treatment of chronic heart failure
MX2014000316A (es) * 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013033324A2 (en) 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US20140364334A1 (en) * 2011-12-21 2014-12-11 Nuclea Biotechnologies, Inc. Congestive heart failure biomarkers
EP2814513B1 (en) 2012-02-14 2017-12-20 The Regents of The University of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
WO2014115033A2 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
HK1211594A1 (en) * 2013-11-07 2016-05-27 上海恒瑞医药有限公司 Human relaxin analogue, pharmaceutical composition of same, and pharmaceutical application of same
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
DK3387019T3 (da) 2015-12-09 2022-01-10 Scripps Research Inst Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US20220008508A1 (en) * 2018-11-20 2022-01-13 Universität Heidelberg Relaxin receptor 1 for use in treatment and prevention of heart failure
US12226455B2 (en) 2019-11-16 2025-02-18 Relaxera Pharmazeutische Gmbh & Co. Kg Medical composition for treating cardiac wasting and cachexia
EP4192580A4 (en) * 2020-08-05 2025-06-18 AskBio Inc. Methods for treating heart disease and congestive heart failure and administration of AAV vectors
RU2748529C1 (ru) * 2020-09-01 2021-05-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ определения этиологии хронической сердечной недостаточности
IL321288A (en) * 2022-12-09 2025-08-01 Astrazeneca Ab Dosing regimens using fusions of relaxin heterodimers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO2002040500A2 (en) * 2000-11-16 2002-05-23 Immundiagnostik Ag Method of prognosis and diagnosis of congestive heart failure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
CA2165781C (en) 1993-06-21 2007-02-13 Tim Breece Process for producing relaxin
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
RU2213559C2 (ru) * 2000-01-26 2003-10-10 Тюменская государственная медицинская академия Способ лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
WO2009007848A2 (en) 2007-07-12 2009-01-15 Compugen Ltd. Bioactive peptides and method of using same
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO2002040500A2 (en) * 2000-11-16 2002-05-23 Immundiagnostik Ag Method of prognosis and diagnosis of congestive heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"View of NCT00520806 on 2008_04_23" [retrieved on 7 September 2011] Retrieved from the internet published 23 April 2008 *

Also Published As

Publication number Publication date
US20160287672A1 (en) 2016-10-06
BRPI0912559A2 (pt) 2015-10-13
MX336145B (es) 2016-01-08
EP2288366A2 (en) 2011-03-02
RU2512933C2 (ru) 2014-04-10
JP2011520917A (ja) 2011-07-21
EP2288366A4 (en) 2012-05-02
US20140005112A1 (en) 2014-01-02
CN104815319A (zh) 2015-08-05
AU2009246112A1 (en) 2009-11-19
EP3150219A1 (en) 2017-04-05
CN102026649A (zh) 2011-04-20
RU2010151470A (ru) 2012-06-27
CA2724535A1 (en) 2009-11-19
JP2017061453A (ja) 2017-03-30
US20110144019A1 (en) 2011-06-16
MX2010012502A (es) 2011-04-11
JP2014237648A (ja) 2014-12-18
WO2009140657A2 (en) 2009-11-19
WO2009140657A3 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
AU2009246112B2 (en) Method of treating chronic heart failure
US9579363B2 (en) Method of lowering mortality
AU2013201629A1 (en) Treating dyspnea associated with acute heart failure with relaxin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired